EMEA-002727-PIP01-19-M01
Key facts
Active substance |
|
Therapeutic area |
Oncology
|
Decision number |
P/0070/2021
|
PIP number |
EMEA-002727-PIP01-19-M01
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of melanoma
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Bristol-Myers Squibb International Corporation
E-mail: medical.information@bms.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-002727-PIP01-19-M01
|
Compliance opinion date |
10/09/2021
|
Compliance outcome |
positive
|